GPC3 and lung cancer: The introduction of the cytoplasmic domain of DAP10 into second-generation CARs M28z and G28z to create M28z10 and G28z10, targeting mesothelin (MSLN) and glypican 3 (GPC3) respectively, resulted in enhanced and prolonged effector function against MSLN+ lung cancer cell lines (63).